Data Sheet (Cat.No.T16280)

TargetMol

Nedocromil

Chemical Properties



CAS No. : 69049-73-6

Formula: C19H17NO7

Molecular Weight: 371.34

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Nedocromil (FPL 59002) inhibits the action or formation of multiple mediators. Which including histamine, leukotriene C4 (LTC4), and prostaglandin D2 (PGD2).
Targets(IC50)	Histamine Receptor,Leukotriene Receptor,Prostaglandin Receptor
In vitro	Nedocromil suppresses the release of histamine, LTC4, and PGD2 from mast cells challenged with antigen with IC30 values of 2.1 μM, 2.3 μM, and 1.9 μM, respectively. It also has anti-human IgE with IC30 values of 4.7 μM, 1.3 μM, and 1.3 μM, respectively[1].
In vivo	Nedocromil can obviously improve cardiac function in mice with diabetic cardiomyopathy, but the treatment cannot restore normal function. Nedocromil-treated diabetic mice display obviously improved heart function compared with controls. However, the cardiac function of Nedocromil-treated diabetic mice remains significantly impaired when compared with normal mice [2].

Solubility Information

Solubility	DMSO: 1 mg/mL (2.69 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.6929 mL	13.4647 mL	26.9295 mL
5 mM	0.5386 mL	2.6929 mL	5.3859 mL
10 mM	0.2693 mL	1.3465 mL	2.6929 mL
50 mM	0.0539 mL	0.2693 mL	0.5386 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Wells E, et al. Characterization of primate bronchoalveolar mast cells. II. Inhibition of histamine, LTC4, and PGD2 release from primate bronchoalveolar mast cells and a comparison with rat peritoneal mastcells. J Immunol. 1986 Dec 15;137(12):3941-5.
Myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation. Huang ZG, et al. PLoS One. 2013;8(3):e60827.